HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Top Medical News

New Prospective Data on Patients With Dravet Syndrome Inform Outcome Measurements in Trials

December 03, 2022

By Matt Hoffman

Data from the BUTTERFLY study of 36 children with Dravet syndrome have provided 12-month measurements of neurodevelopment, clinical status, quality of life, and executive function. Investigators expressed that these data will help inform future trial outcome measures.

The Pediatric Epilepsy Learning Healthcare System Provides Big Data to Answer Big Questions

December 03, 2022

By Isabella Ciccone, MPH

Zachary Grinspan, MD, MS, a pediatric epilepsy specialist at Weill Cornell Medicine, in New York City, spoke about the analysis of large amounts of data on pediatric epilepsy at the 2022 American Epilepsy Society Annual Meeting.

Mirtazapine and Carbamazepine Fail to Demonstrate Clinical and Cost Effectiveness as Alzheimer Agitation Treatments

December 03, 2022

By Marco Meglio

Over a 12-week treatment period, investigators found no significant differences in mean Cohen Mansfield Agitation Inventory scores between mirtazapine and placebo, with similar rates in adverse events.

NeurologyLive® Friday 5 — December 2, 2022

December 02, 2022

By NeurologyLive® Staff

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 2, 2022.

Brexpiprazole Continues to Demonstrate Efficacy as Alzheimer Agitation Therapy Across Multiple Phase 3 Trials

December 02, 2022

By Marco Meglio

Across 3 trials in patients with Alzheimer disease agitation, brexpiprazole doses of 2 or 3 mg/day was safe and showed a statistically significant improvement vs placebo in agitation.

Featured


Latest Videos


Most Recent